An investigational vaginal gel was found to significantly decrease urogenital chlamydia and gonorrhea in women at high risk for infection, in comparison with placebo, in a randomized trial published in the American Journal of Obstetrics and Gynecology.

EVO100, an investigational antimicrobial, bioadhesive vaginal gel, contains L-lactic acid, citric acid, and potassium bitartrate. Investigators assessed the efficacy and safety of this gel in the AMPREVENCE study in the prevention of chlamydia and gonorrhea.EVO100 led to a significant reduction in STI incidence for both types of STIs. Chlamydia trachomatis infection rate among EVO100 users was 4.8% compared to 9.7% in placebo users. In the Neisseria gonorrhoeae-analysis–eligible women, infection rates were 0.7%, compared to 3.2% in the placebo group… (Medscape)